TB-500 (Thymosin Beta-4)

peptideresearch peptide

Research chemical — not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.

At a glance

Best for
Not established — investigational
Main caution
No human trials of the marketed product; unregulated purity and a pro-angiogenic mechanism of unknown long-term risk
Evidence strength: Preclinical/animal only; no approved human use

What is it

TB-500 is a synthetic peptide marketed as a fragment related to Thymosin Beta-4, a naturally occurring actin-binding protein involved in cell migration and tissue repair. It is proposed to support wound healing, angiogenesis, and reduced inflammation by promoting actin regulation and cell migration. Evidence is almost entirely preclinical (animal and cell models, often using full-length Thymosin Beta-4 rather than the marketed fragment); there are no controlled human trials of the 'TB-500' research product establishing safety or efficacy. It is not FDA-approved, is not a dietary supplement, and is sold only 'for research use only.'

Is it worth it for you?

Probably skip if…

  • You expect an approved or proven therapy — it is neither FDA-approved nor a supplement
  • You would source it from 'research use only' vendors with no purity or sterility controls
  • You are not comfortable with completely unknown long-term safety in humans
  • You want to avoid injection risks such as infection and contamination
  • You compete in sport — it is prohibited under WADA anti-doping rules

Safety

Common side effects

Not well characterized in humans — no controlled trials define a side-effect profile

Serious risks

  • Unregulated purity, sterility, and dosing of research-grade product
  • Unknown long-term effects, including theoretical concerns about promoting growth of existing tumors via angiogenesis
  • Injection-related infection and contamination risk
  • No clinical monitoring or dosing oversight

Who should avoid it

  • Anyone without direct medical supervision
  • Pregnancy and breastfeeding
  • People with cancer or a history of cancer
  • Competitive athletes subject to anti-doping rules

Pregnancy & breastfeeding

Avoid — no safety data.

Choosing a product

Be skeptical of

  • 'Proven' healing, recovery, or anti-injury claims in humans
  • Vendors selling 'for research use only' product for human injection
  • 'Miracle' or guaranteed regeneration/anti-aging claims

Track TB-500 (Thymosin Beta-4) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 30, 2026·Evidence current as of May 30, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.